Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus

Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.

NCT00770653 ·Status: COMPLETED ·Phase: PHASE3

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

NCT02314637 ·Status: COMPLETED ·Phase: PHASE3

Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus

NCT02024971 ·Status: COMPLETED

Safety Study of Pioglitazone Compared To Glyburide on Liver Function

NCT00494312 ·Status: COMPLETED ·Phase: PHASE4

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

NCT01107717 ·Status: COMPLETED ·Phase: PHASE4

Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes

NCT00367055 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

NCT00402909 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

NCT00499707 ·Status: COMPLETED ·Phase: PHASE3

Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

NCT02220907 ·Status: COMPLETED ·Phase: PHASE3

Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin

NCT02426294 ·Status: UNKNOWN ·Phase: PHASE4

Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"

NCT02002975 ·Status: COMPLETED

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762736 ·Status: COMPLETED ·Phase: PHASE2

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

NCT02887625 ·Status: UNKNOWN ·Phase: NA

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

NCT01940965 ·Status: COMPLETED ·Phase: PHASE3

Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"

NCT02068508 ·Status: COMPLETED

Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients

NCT02099838 ·Status: COMPLETED ·Phase: PHASE4

Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.

NCT00770445 ·Status: COMPLETED ·Phase: PHASE4

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications

NCT02678676 ·Status: COMPLETED

Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

NCT00521742 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

NCT02926937 ·Status: COMPLETED ·Phase: PHASE3

An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients

NCT01453049 ·Status: TERMINATED ·Phase: PHASE3

24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes

NCT00318656 ·Status: COMPLETED ·Phase: PHASE4

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

NCT01990300 ·Status: COMPLETED

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013 ·Status: COMPLETED ·Phase: PHASE3